The highlights of the ERS 2019 congress, explained by Jan De Backer, CEO of Fluidda

During the past years, the treatment of lung diseases is shifting from using more common bronchodilatators to more personalized medicine with biologicals and new devices.

This shift  calls for new diagnostic tools to match the heterogeneity of the patients with the heterogeneity of treatments to optimize the treatment of every individual patient..

Jan de Backer, CEO of Fluidda, explains why.

Categorised in: / October 24, 2019 4:21 pm / Published by